Corrigendum to "A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD" [Respir. Med. 120 November 2016 16-24]

Affiliations

¹ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: DTashkin@mednet.ucla.edu.
² Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
³ Servei de Pneumologia, Institut del Tòrax, Hospital Clínic-IDIBAPS-CIBERES, University of Barcelona, Barcelona, Spain.
⁴ Spartanburg Medical Research, Spartanburg, SC, USA.
⁵ Pulmonary Associates, Phoenix, AZ, USA.
⁶ Clinical Research of Rock Hill, Rock Hill, SC, USA.
⁷ New Horizons Clinical Research, Cincinnati, OH, USA.
⁸ University of North Carolina School of Medicine, Chapel Hill, NC, USA.
⁹ Pearl Therapeutics Inc., Morristown, NJ, USA.
¹⁰ Pearl Therapeutics Inc., Durham, NC, USA.

Free article

Published Erratum

Donald P Tashkin et al. Respir Med. 2017 Aug.

Free article

. 2017 Aug:129:164.

doi: 10.1016/j.rmed.2017.06.011. Epub 2017 Jun 30.

¹ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: DTashkin@mednet.ucla.edu.
² Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
³ Servei de Pneumologia, Institut del Tòrax, Hospital Clínic-IDIBAPS-CIBERES, University of Barcelona, Barcelona, Spain.
⁴ Spartanburg Medical Research, Spartanburg, SC, USA.
⁵ Pulmonary Associates, Phoenix, AZ, USA.
⁶ Clinical Research of Rock Hill, Rock Hill, SC, USA.
⁷ New Horizons Clinical Research, Cincinnati, OH, USA.
⁸ University of North Carolina School of Medicine, Chapel Hill, NC, USA.
⁹ Pearl Therapeutics Inc., Morristown, NJ, USA.
¹⁰ Pearl Therapeutics Inc., Durham, NC, USA.

No abstract available

Erratum for

A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD.
Tashkin DP, Martinez FJ, Rodriguez-Roisin R, Fogarty C, Gotfried M, Denenberg M, Gottschlich G, Donohue JF, Orevillo C, Darken P, St Rose E, Strom S, Fischer T, Golden M, Reisner C. Tashkin DP, et al. Respir Med. 2016 Nov;120:16-24. doi: 10.1016/j.rmed.2016.09.012. Epub 2016 Sep 17. Respir Med. 2016. PMID: 27817811 Clinical Trial.